Transmembrane peptide 4 and 5 of APJ are essential for its heterodimerization with OX1R
Increasing evidence indicates some G protein-coupled receptors function as a heterodimer, which provide a novel target for therapeutics investigation. However, study on the receptor-receptor interaction interface, a potent target on interfering dimer formation, are still limited. Here, using biolumi...
Saved in:
| Published in | Biochemical and biophysical research communications Vol. 521; no. 2; pp. 408 - 413 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
08.01.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0006-291X 1090-2104 1090-2104 |
| DOI | 10.1016/j.bbrc.2019.10.146 |
Cover
| Summary: | Increasing evidence indicates some G protein-coupled receptors function as a heterodimer, which provide a novel target for therapeutics investigation. However, study on the receptor-receptor interaction interface, a potent target on interfering dimer formation, are still limited. Here, using bioluminescence resonance energy transfer (BRET) combined with co-immunoprecipitation (Co-IP), we found a new constitutive GPCR heterodimer, apelin receptor (APJ)-orexin receptor type 1 (OX1R). Both APJ and OX1R co-internalized when constantly subjected to cognate agonist (apelin-13 or orexin-A) specific to either protomer. Combined with BRET and immunostaining, the in vitro synthesized transmembrane peptides (TMs) interfering experiments suggests that TM4 and 5 of APJ act as the interaction interface of the APJ-OX1R heterodimer, and co-internalization could be disrupted by these peptides as well. Our study not only provide new evidence on GPCR heterodimerization, but address a novel heterodimerization interface, which can be severed as a potential pharmacological target.
•APJ and OX1R could form a constitutive heterodimer.•Transmembrane peptides 4 and 5 serve as the interaction interface of the dimer.•Both protomers co-internalize when subject to agonist specific to either protomer. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0006-291X 1090-2104 1090-2104 |
| DOI: | 10.1016/j.bbrc.2019.10.146 |